Our
Research
One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable.” Our research group is reimagining druggability by using chemoproteomic approaches to tackle the undruggable proteome.

Featured Publications
Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC
Boike L*, Cioffi AG*, Majewski FC, Co J, Henning NJ, Jones MD, Liu G, McKenna JM, Tallarico JA, Schirle M, Nomura DK.
Cell Chemical Biology, 2021, 28, 4-13. PMID 32966806 (*co-first authorship) (Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Manumycin polyketides act as molecular glues between UBR7 and P53
Isobe Y, Okumura M, White R, McGregor LM, Brittain SM, Jones MD, Liang X, White R, Forrester W, McKenna JM, Tallarico JA, Schirle M, Maimone TJ*, Nomura DK*
Nature Chemical Biology, 2020, 16, 1189-1198. PMID 32572277 (*co-corresponding author) (Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ*, Nomura DK*
Nature Chemical Biology, 2019, 15, 747-755. PMID 31209351 (*co-corresponding authors) (Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Latest
Tweets
Follow us on Twitter @DanNomura